<unk>  is a tyrosine kinase inhibitor that is FDA approved for the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to a previous treatment.   Common adverse reactions include diarrhea, hypertension, nausea, respiratory infection, dizziness, ALT/AST increased, rash, abdominal pain, fatigue, chest pain and neutropenia.
Fostamatinib
Neratinib
Dasatinib
Brigatinib
Lenvatinib
Lorlatinib
Afatinib
Dabrafenib mesylate